Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.actatropica.2020.105778

http://scihub22266oqcxt.onion/10.1016/j.actatropica.2020.105778
suck pdf from google scholar
33253656!7695590!33253656
unlimited free pdf from europmc33253656    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33253656      Acta+Trop 2021 ; 214 (ä): 105778
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • One year update on the COVID-19 pandemic: Where are we now? #MMPMID33253656
  • Mishra SK; Tripathi T
  • Acta Trop 2021[Feb]; 214 (ä): 105778 PMID33253656show ga
  • We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech's BNT162b2, Moderna's mRNA-1273, University of Oxford & AstraZeneca's AZD1222, and Gamaleya's Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic's 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics. The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics.
  • |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH]
  • |Alanine/analogs & derivatives/therapeutic use[MESH]
  • |Amides/therapeutic use[MESH]
  • |Animals[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |COVID-19 Vaccines[MESH]
  • |COVID-19/immunology/*therapy/transmission[MESH]
  • |Chloroquine/therapeutic use[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Coronavirus Infections/transmission[MESH]
  • |Coronavirus/genetics[MESH]
  • |Drug Combinations[MESH]
  • |Drug Repositioning[MESH]
  • |Glucocorticoids/therapeutic use[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Indoles/therapeutic use[MESH]
  • |Ivermectin/therapeutic use[MESH]
  • |Lopinavir/therapeutic use[MESH]
  • |Mutation[MESH]
  • |Pandemics[MESH]
  • |Phytotherapy[MESH]
  • |Plant Extracts/therapeutic use[MESH]
  • |Pyrazines/therapeutic use[MESH]
  • |Ritonavir/therapeutic use[MESH]
  • |SARS-CoV-2/genetics/immunology/pathogenicity[MESH]
  • |Spike Glycoprotein, Coronavirus[MESH]
  • |Tinospora[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box